133 related articles for article (PubMed ID: 11350116)
1. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1.
Watt F; Martorana A; Brookes DE; Ho T; Kingsley E; O'Keefe DS; Russell PJ; Heston WD; Molloy PL
Genomics; 2001 May; 73(3):243-54. PubMed ID: 11350116
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer.
Noss KR; Wolfe SA; Grimes SR
Gene; 2002 Feb; 285(1-2):247-56. PubMed ID: 12039052
[TBL] [Abstract][Full Text] [Related]
3. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen.
Lee SJ; Lee K; Yang X; Jung C; Gardner T; Kim HS; Jeng MH; Kao C
J Mol Biol; 2003 Jul; 330(4):749-60. PubMed ID: 12850144
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
O'Keefe DS; Uchida A; Bacich DJ; Watt FB; Martorana A; Molloy PL; Heston WD
Prostate; 2000 Oct; 45(2):149-57. PubMed ID: 11027414
[TBL] [Abstract][Full Text] [Related]
5. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.
Cleutjens KB; van der Korput HA; van Eekelen CC; van Rooij HC; Faber PW; Trapman J
Mol Endocrinol; 1997 Feb; 11(2):148-61. PubMed ID: 9013762
[TBL] [Abstract][Full Text] [Related]
6. Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer.
Peng W; Guo L; Tang R; Liu X; Jin R; Dong JT; Xing CG; Zhou W
Prostate; 2019 Mar; 79(4):370-378. PubMed ID: 30488457
[TBL] [Abstract][Full Text] [Related]
7. Novel prostate-specific promoter derived from PSA and PSMA enhancers.
Lee SJ; Kim HS; Yu R; Lee K; Gardner TA; Jung C; Jeng MH; Yeung F; Cheng L; Kao C
Mol Ther; 2002 Sep; 6(3):415-21. PubMed ID: 12231179
[TBL] [Abstract][Full Text] [Related]
8. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
9. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase.
Bacich DJ; Pinto JT; Tong WP; Heston WD
Mamm Genome; 2001 Feb; 12(2):117-23. PubMed ID: 11210180
[TBL] [Abstract][Full Text] [Related]
10. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.
Ikegami S; Tadakuma T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
Jpn J Cancer Res; 2002 Oct; 93(10):1154-63. PubMed ID: 12417046
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
12. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y
Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471
[TBL] [Abstract][Full Text] [Related]
13. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.
Zeng H; Wu Q; Li H; Wei Q; Lu Y; Li X; Wang F; Zhao F; Ding Z; Yang Y
J Androl; 2005; 26(2):215-21. PubMed ID: 15713827
[TBL] [Abstract][Full Text] [Related]
14. Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines.
Noss KR; Singal R; Grimes SR
Anticancer Res; 2002; 22(3):1505-11. PubMed ID: 12168830
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of human T-plastin gene in leukocytes and non-leukocytes: identification of the promoter, enhancer, and CpG island.
Lin CS; Lau A; Huynh T; Lue TF
DNA Cell Biol; 1999 Jan; 18(1):27-37. PubMed ID: 10025506
[TBL] [Abstract][Full Text] [Related]
16. [Constructing recombinant plasmid with prostate-specific membrane antigen promoter and reverse enhancer and comparing the transcription activity of enhancers in different directions].
Zeng H; Liao YC; Wang F; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Nov; 36(6):782-5. PubMed ID: 16334552
[TBL] [Abstract][Full Text] [Related]
17. [The construction of recombinant plasmid with prostate-specific membrane antigen promoter controlling reporter gene expression].
Zeng H; Li H; Liao YC; Li X; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):169-71. PubMed ID: 15807257
[TBL] [Abstract][Full Text] [Related]
18. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
19. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.
O'Keefe DS; Su SL; Bacich DJ; Horiguchi Y; Luo Y; Powell CT; Zandvliet D; Russell PJ; Molloy PL; Nowak NJ; Shows TB; Mullins C; Vonder Haar RA; Fair WR; Heston WD
Biochim Biophys Acta; 1998 Nov; 1443(1-2):113-27. PubMed ID: 9838072
[TBL] [Abstract][Full Text] [Related]
20. Androgen specificity of a response unit upstream of the human secretory component gene is mediated by differential receptor binding to an essential androgen response element.
Verrijdt G; Schoenmakers E; Alen P; Haelens A; Peeters B; Rombauts W; Claessens F
Mol Endocrinol; 1999 Sep; 13(9):1558-70. PubMed ID: 10478846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
